CLIA Waiver for QuickVue® RSV Test
go back to news archives| Quidel Corporation has announced that the U.S. Food and Drug Administration (FDA) granted CLIA waiver for the QuickVue® RSV test for the qualitative detection of respiratory syncytial virus (RSV). The waiver makes the QuickVue RSV test more widely available for use, especially in physician offices and clinics where waived tests are used most frequently. The QuickVue RSV test is simple and accurate, with high sensitivity and specificity. Respiratory syncytial virus is recognized by the American Academy of Pediatrics as the leading cause of pneumonia and bronchiolitis among children two years of age and younger. RSV is a common virus with symptoms that often resemble the common cold. The QuickVue RSV test is intended for use as an aid in the diagnosis of acute RSV viral infections for symptomatic pediatric patients. |
NOTE: This item is from our 'historic' database and
may contain information which is not up to date.
Source : Quidel Corporation View Company Information
Posted on March 7, 2008
advertisement
advertisement
advertisement
advertisement
LATEST MICROBIOLOGY NEWS
MICROBIOLOGY EVENTS
-
Mycotoxin Detection and Analysis: Strategies to Support Your Testing Program
-
15th Conference of The World Mycotoxin Forum® – WMFmeetsSalzburg
-
ESCMID European Congress of Clinical Microbiology and Infectious Diseases
-
IBQC 2025
-
IFU Technical Workshop 2025
-
Validation of Water Systems for Microbial Control
-
USP Chapter <86> and the Move to Recombinant Methods
-
Free Expert Webinar: Advancing Drinking Water Microbiology Testing Compliance & Efficiency
-
British Society For Microbial Technology 40th Anniversary Microbiology Conference
-
Sampling and Microbial Testing of Water and Data Trending
